• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肝移植后肝细胞癌的预后:与肝部分切除术的比较分析

Prognosis of Hepatocellular Carcinoma after Liver Transplantation: Comparative Analysis with Partial Hepatectomy.

作者信息

Lee Kyuho, Lee Kyoung-Bun, Yi Nam-Joon, Suh Kyung-Suk, Jang Ja-June

机构信息

Department of Pathology, Seoul National University College of Medicine, Seoul, Korea.

Department of Surgery, Seoul National University College of Medicine, Seoul, Korea.

出版信息

J Pathol Transl Med. 2017 Jan;51(1):79-86. doi: 10.4132/jptm.2016.10.13. Epub 2016 Dec 25.

DOI:10.4132/jptm.2016.10.13
PMID:28013531
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5282549/
Abstract

BACKGROUND

Liver transplantation (LT) is the treatment of choice for hepatocellular carcinoma (HCC). The aim of this study was to investigate the recurrence rate of HCC after LT and prognostic factors for recurrence by comparing LT with non-transplanted resection.

METHODS

The participants were 338 patients who underwent LT between 1996 and 2012 at Seoul National University Hospital (LT group) and 520 HCC patients who underwent partial hepatectomy between 1995 and 2006 (control group, non-LT group).

RESULTS

In the LT group, 68 of 338 patients (19.8%) showed relapse, and the recurrence rate was lower than that in the non-LT group (64.9%, 357/520, p < .001). Stratification analysis by American Joint Committee on Cancer (AJCC) stage showed that the stage I-II LT group had a lower recurrence rate than the non-LT group. Univariate comparative analysis demonstrated that multiplicity of tumor, tumor size, gross type, Edmondson- Steiner (ES) nuclear grade, extent of tumor, angioinvasion, AJCC stage, Milan criteria, University of California at San Francisco criteria on explant pathology (all p < .001), positive expression of cytokeratin 19 (p = .002), and preoperative α-fetoprotein (AFP) (p < .001) were predictors of tumor recurrence. In multivariate analysis, LT, preoperative AFP, multiplicity of tumor, extent of tumor, size of tumor, and ES nuclear grade were independent prognostic factors.

CONCLUSIONS

LT might have a protective effect against the late recurrence of stage I-II HCC compared to non-LT, and the prognostic factors for recurrence were similar to previously well-known prognostic factors for HCC.

摘要

背景

肝移植(LT)是肝细胞癌(HCC)的首选治疗方法。本研究旨在通过比较肝移植与非移植性肝切除术,探讨肝移植术后肝癌的复发率及复发的预后因素。

方法

研究对象为1996年至2012年在首尔国立大学医院接受肝移植的338例患者(肝移植组)和1995年至2006年接受部分肝切除术的520例肝癌患者(对照组,非肝移植组)。

结果

肝移植组338例患者中有68例(19.8%)出现复发,复发率低于非肝移植组(64.9%,357/520,p<.001)。美国癌症联合委员会(AJCC)分期的分层分析显示,I-II期肝移植组的复发率低于非肝移植组。单因素比较分析表明,肿瘤的多灶性、肿瘤大小、大体类型、埃德蒙森-斯坦纳(ES)核分级、肿瘤范围、血管侵犯、AJCC分期、米兰标准、加利福尼亚大学旧金山分校外植体病理学标准(均p<.001)、细胞角蛋白19的阳性表达(p=.002)和术前甲胎蛋白(AFP)(p<.001)是肿瘤复发的预测因素。多因素分析中,肝移植、术前AFP、肿瘤多灶性、肿瘤范围、肿瘤大小和ES核分级是独立的预后因素。

结论

与非肝移植相比,肝移植可能对I-II期肝癌的晚期复发具有保护作用,复发的预后因素与既往熟知的肝癌预后因素相似。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/23ec/5282549/62dc018342b9/jptm-2016-10-13f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/23ec/5282549/684733fd64e3/jptm-2016-10-13f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/23ec/5282549/62dc018342b9/jptm-2016-10-13f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/23ec/5282549/684733fd64e3/jptm-2016-10-13f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/23ec/5282549/62dc018342b9/jptm-2016-10-13f2.jpg

相似文献

1
Prognosis of Hepatocellular Carcinoma after Liver Transplantation: Comparative Analysis with Partial Hepatectomy.肝移植后肝细胞癌的预后:与肝部分切除术的比较分析
J Pathol Transl Med. 2017 Jan;51(1):79-86. doi: 10.4132/jptm.2016.10.13. Epub 2016 Dec 25.
2
A novel prognostic nomogram accurately predicts hepatocellular carcinoma recurrence after liver transplantation: analysis of 865 consecutive liver transplant recipients.一种新型预后列线图可准确预测肝移植后肝细胞癌复发:对865例连续肝移植受者的分析
J Am Coll Surg. 2015 Apr;220(4):416-27. doi: 10.1016/j.jamcollsurg.2014.12.025. Epub 2014 Dec 27.
3
Risk factors of hepatocellular carcinoma recurrence after liver transplantation: accuracy of the alpha-fetoprotein model in a single-center experience.肝移植后肝细胞癌复发的危险因素:单中心经验中甲胎蛋白模型的准确性
Transplant Proc. 2015 Jan-Feb;47(1):84-9. doi: 10.1016/j.transproceed.2014.12.013.
4
Liver transplantation for hepatocellular carcinoma within the Milan criteria versus the University of California San Francisco criteria: a comparative study.米兰标准与加州大学旧金山分校标准下肝细胞癌肝移植的比较研究
Eur J Gastroenterol Hepatol. 2018 Apr;30(4):398-403. doi: 10.1097/MEG.0000000000001044.
5
Alpha-Fetoprotein Slope >7.5 ng/mL per Month Predicts Microvascular Invasion and Tumor Recurrence After Liver Transplantation for Hepatocellular Carcinoma.甲胎蛋白斜率>7.5ng/ml/月预测肝癌肝移植后微血管侵犯和肿瘤复发。
Transplantation. 2018 May;102(5):816-822. doi: 10.1097/TP.0000000000002094.
6
Number and tumor size are not sufficient criteria to select patients for liver transplantation for hepatocellular carcinoma.肿瘤数目和大小均不是选择肝癌患者进行肝移植的充分标准。
Ann Surg Oncol. 2012 Jun;19(6):2020-6. doi: 10.1245/s10434-011-2170-9. Epub 2011 Dec 17.
7
Endothelial angiopoietin-2 overexpression in explanted livers identifies subjects at higher risk of recurrence of hepatocellular carcinoma after liver transplantation.移植肝中内皮血管生成素-2的过表达可识别肝移植后肝细胞癌复发风险较高的患者。
Front Oncol. 2022 Sep 8;12:960808. doi: 10.3389/fonc.2022.960808. eCollection 2022.
8
Liver resection as a bridge to transplantation for hepatocellular carcinoma on cirrhosis: a reasonable strategy?肝切除术作为肝硬化合并肝细胞癌患者肝移植的过渡手段:一种合理的策略?
Ann Surg. 2003 Oct;238(4):508-18; discussion 518-9. doi: 10.1097/01.sla.0000090449.87109.44.
9
Advantage of early liver transplantation whenever indicated for hepatocellular carcinoma recurrence after primary liver resection.对于原发性肝癌切除术后肝癌复发,只要有指征,早期肝移植的优势。
Biomed J. 2019 Oct;42(5):335-342. doi: 10.1016/j.bj.2019.04.001. Epub 2019 Oct 29.
10
Metroticket 2.0 Model for Analysis of Competing Risks of Death After Liver Transplantation for Hepatocellular Carcinoma.Metroticket 2.0 模型分析肝癌肝移植术后死亡的竞争风险。
Gastroenterology. 2018 Jan;154(1):128-139. doi: 10.1053/j.gastro.2017.09.025. Epub 2017 Oct 5.

引用本文的文献

1
Locoregional and Surgical Treatment of Single-Nodule Hepatocellular Carcinoma Recurrence After Liver Transplantation: A Systematic Review and a Meta-Analysis.肝移植后单结节肝细胞癌复发的局部区域及手术治疗:一项系统评价与荟萃分析
Cancers (Basel). 2025 Apr 29;17(9):1501. doi: 10.3390/cancers17091501.
2
Ten-year survival and recurrence of hepatocellular cancer.肝细胞癌的十年生存率及复发情况
Hepatoma Res. 2019;5. doi: 10.20517/2394-5079.2019.013. Epub 2019 Oct 13.
3
A model combining TNM stage and tumor size shows utility in predicting recurrence among patients with hepatocellular carcinoma after resection.

本文引用的文献

1
Impact of Histological Factors of Hepatocellular Carcinoma on the Outcome of Liver Transplantation.肝细胞癌组织学因素对肝移植结局的影响
Transplant Proc. 2016 Jul-Aug;48(6):1968-77. doi: 10.1016/j.transproceed.2016.04.002.
2
Hepatocellular carcinoma recurrence pattern following liver transplantation and a suggested surveillance algorithm.肝移植后肝细胞癌复发模式及建议的监测算法
Clin Imaging. 2016 Nov-Dec;40(6):1131-1134. doi: 10.1016/j.clinimag.2016.07.002. Epub 2016 Jul 7.
3
Incidence, Characteristics, and Prognosis of Incidentally Discovered Hepatocellular Carcinoma after Liver Transplantation.
一种结合TNM分期和肿瘤大小的模型在预测肝细胞癌患者切除术后的复发方面显示出实用性。
Cancer Manag Res. 2018 Sep 20;10:3707-3715. doi: 10.2147/CMAR.S175303. eCollection 2018.
肝移植后偶然发现的肝细胞癌的发病率、特征及预后
J Transplant. 2016;2016:1916387. doi: 10.1155/2016/1916387. Epub 2016 Jun 15.
4
Progenitor cell markers predict outcome of patients with hepatocellular carcinoma beyond Milan criteria undergoing liver transplantation.祖细胞标志物可预测米兰标准以外行肝移植的肝细胞癌患者的预后。
J Hepatol. 2015 Dec;63(6):1368-77. doi: 10.1016/j.jhep.2015.07.025. Epub 2015 Jul 26.
5
Long-term outcomes of hepatic resection versus living donor liver transplantation for hepatocellular carcinoma: a propensity score-matching study.肝细胞癌肝切除与活体肝移植的长期结局:一项倾向评分匹配研究。
Dis Markers. 2015;2015:425926. doi: 10.1155/2015/425926. Epub 2015 Apr 1.
6
2014 KLCSG-NCC Korea Practice Guideline for the Management of Hepatocellular Carcinoma.2014年韩国肝脏研究学会-国立癌症中心肝细胞癌管理韩国实践指南
Gut Liver. 2015 May 23;9(3):267-317. doi: 10.5009/gnl14460.
7
Targeting of circulating hepatocellular carcinoma cells to prevent postoperative recurrence and metastasis.针对循环肝癌细胞以预防术后复发和转移。
World J Gastroenterol. 2014 Jan 7;20(1):142-7. doi: 10.3748/wjg.v20.i1.142.
8
Circulating tumor cells in hepatocellular carcinoma: detection techniques, clinical implications, and future perspectives.循环肿瘤细胞在肝细胞癌中的检测技术、临床意义及未来展望。
Semin Oncol. 2012 Aug;39(4):449-60. doi: 10.1053/j.seminoncol.2012.05.012.
9
Utilizing circulating tumor cells: challenges and pitfalls.利用循环肿瘤细胞:挑战与陷阱。
Curr Opin Genet Dev. 2011 Feb;21(1):50-8. doi: 10.1016/j.gde.2010.10.010. Epub 2010 Nov 26.
10
The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM.美国癌症联合委员会:第 7 版 AJCC 癌症分期手册与 TNM 的未来。
Ann Surg Oncol. 2010 Jun;17(6):1471-4. doi: 10.1245/s10434-010-0985-4.